替尔泊肽对2型糖尿病患者血脂和代谢物谱的影响
这项2b期试验的事后探索性分析纳入259例2型糖尿病患者,比较替尔泊肽、度拉糖肽或安慰剂治疗26周后的代谢组和脂质组变化。替尔泊肽调节与胰岛素抵抗、肥胖及未来2型糖尿病风险相关的代谢物和脂质,且变化幅度与HbA1c、HOMA2-IR及胰岛素原降低成比例。
要点
- 替尔泊肽降低支链氨基酸及其分解产物,变化与血糖和胰岛素抵抗改善相关。
- 替尔泊肽显著降低甘油三酯和甘油二酯,且偏向短链和高饱和种类。
- 代谢物调节部分独立于体重下降,方向与代谢健康改善一致。
核心结论
- 替尔泊肽降低体重、改善血糖控制,并独特调节与2型糖尿病风险和代谢紊乱相关的代谢物。
研究设计与样本
- 2b期试验的事后探索性代谢组学和脂质组学分析,259例2型糖尿病患者随机接受每周皮下替尔泊肽(1、5、10、15 mg)、度拉糖肽(1.5 mg)或安慰剂治疗26周。
主要发现
- 与基线及安慰剂相比,高剂量替尔泊肽调节与胰岛素抵抗、肥胖和未来2型糖尿病风险相关的代谢物和脂质簇。
- 支链氨基酸、直接分解产物谷氨酸、3-羟基异丁酸、支链酮酸及间接副产物2-羟基丁酸较基线和安慰剂下降。
- 替尔泊肽的这些变化显著大于度拉糖肽,且与HbA1c、HOMA2-IR指数和胰岛素原降低成比例。
- 甘油三酯和甘油二酯较基线、度拉糖肽和安慰剂显著降低,且偏向短链和高饱和种类。
临床怎么用
- 替尔泊肽可能通过改善支链氨基酸和脂质代谢谱带来额外代谢获益,但代谢组学变化目前仅供研究参考。
局限性
- 为事后探索性分析,代谢组学和脂质组学结果需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Tirzepatide substantially reduced hemoglobin A1c (HbA1c) and body weight in subjects with type 2 diabetes (T2D) compared with the glucagon-like peptide 1 receptor agonist dulaglutide. Improved glycemic control was associated with lower circulating triglycerides and lipoprotein markers and improved markers of beta-cell function and insulin resistance (IR), effects only partially attributable to weight loss. OBJECTIVE: Assess plasma metabolome changes mediated by tirzepatide. DESIGN: Phase 2b trial participants were randomly assigned to receive weekly subcutaneous tirzepatide, dulaglutide, or placebo for 26 weeks. Post hoc exploratory metabolomics and lipidomics analyses were performed. SETTING: Post hoc analysis. PARTICIPANTS: 259 subjects with T2D. INTERVENTION(S): Tirzepatide (1, 5, 10, 15 mg), dulaglutide (1.5 mg), or placebo. MAIN OUTCOME MEASURE(S): Changes in metabolite levels in response to tirzepatide were assessed against baseline levels, dulaglutide, and placebo using multiplicity correction. RESULTS: At 26 weeks, a higher dose tirzepatide modulated a cluster of metabolites and lipids associated with IR, obesity, and future T2D risk. Branched-chain amino acids, direct catabolic products glutamate, 3-hydroxyisobutyrate, branched-chain ketoacids, and indirect byproducts such as 2-hydroxybutyrate decreased compared to baseline and placebo. Changes were significantly larger with tirzepatide compared with dulaglutide and directly proportional to reductions of HbA1c, homeostatic model assessment 2-IR indices, and proinsulin levels. Proportional to metabolite changes, triglycerides and diglycerides were lowered significantly compared to baseline, dulaglutide, and placebo, with a bias toward shorter and highly saturated species. CONCLUSIONS: Tirzepatide reduces body weight and improves glycemic control and uniquely modulates metabolites associated with T2D risk and metabolic dysregulation in a direction consistent with improved metabolic health.
引用
- Pirro V, Roth KD, Lin Y, et al. Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes. J Clin Endocrinol Metab. 2022. PMID: 34608929. doi:10.1210/clinem/dgab722
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。